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Summary
Thrombotic thrombocytopenic purpura (TTP) and atypical
haemolytic uraemic syndrome (aHUS) are acute, rare life-
threatening thrombotic microangiopathies that require rapid
diagnosis and treatment. They are deﬁned by microangio-
pathic haemolytic anaemia and thrombocytopenia, with renal
involvement primarily in aHUS and neurological and cardio-
logical sequelae in TTP. Prompt treatment for most cases of
both conditions is with plasma exchange initially and mono-
clonal therapy (rituximab in TTP and eculizumab in aHUS)
as the mainstay of therapy. Here we discuss the diagnosis
and therapy for both disorders.
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The last 10 years has been associated with a paradigm shift
in our understanding, diagnosis, treatment and continuing
clinical and basic research into Thrombotic thrombocytope-
nic purpura (TTP) and atypical haemolytic uraemic syn-
drome (aHUS) and other thrombotic microangiopathies
(TMAs). Here we will concentrate speciﬁcally on TTP and
aHUS, which, for many years were considered to be the same
disease, but it is now clear that their pathophysiology and
therapies are quite distinct. TTP results from a deﬁciency of
ADAMTS13 (a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13), a serine metallo-
protease required for the cleavage of von Willebrand factor
(VWF). In the majority of cases, the low ADAMTS13 levels
are due to Anti-ADAMTS13 autoantibodies and an underly-
ing disturbance in immune function. aHUS is the conse-
quence of dysregulation of the complement system associated
with gain- or loss-of-function mutations causing excessive
complement activation.
However, in both disorders, further environmental
and possible genetic triggers will be needed for disease
presentation.
Diagnosis of TTP and aHUS
The underlying pathophysiology of TTP is the presence of
widespread microthrombi that are platelet- and VWF-rich.
aHUS is associated with platelet ﬁbrin thrombi, but other
TMAs have varying amounts of lymphocytic or neutrophil
inﬁltration as part of, or related to, the microthrombi
(Hosler et al, 2003).
Previously, TTP was diagnosed as a pentad (thrombocyto-
penia, microangiopathic haemolytic anaemia (MAHA), neu-
rological features, fever and renal involvement) and HUS was
classiﬁed by the presence or absence of bloody diarrhoea.
Indeed, the relevance of ‘diarrhoea negative’ HUS was
unclear. This has now changed, and central to the diagnosis
of TMAs is thrombocytopenia, MAHA and the clinical or
histological effects of microvascular thrombosis. The degree
of thrombocytopenia at initial presentation of TTP and
aHUS is, broadly, <50 9 10
9/l for TTP and usually
>50 9 10
9/l for aHUS. However, this is only a general rule
and TTP cases with platelet counts >50 9 10
9/l and aHUS
cases with platelet counts <50 9 10
9/l can be recalled and
are not anecdotal. Therefore, a clinical suspicion and full
diagnostic work up is required. Presentation may not be
‘classic’. In patients presenting with neurological, cardiac or
bleeding symptoms (such as haematuria) as an emergency,
and is associated with thrombocytopenia, TTP should be
considered. The presence of neurological and cardiological
involvement signiﬁes severe disease and should be consid-
ered, especially in young patients. At least 10% of presenting
TTP patients require intubation and ventilation. Identiﬁca-
tion of subgroups of TTP, such as human immunodeﬁciency
virus (HIV)-associated, pregnancyand drug-related cases,
require associated treatment of the underlying condition as
well as plasma exchange (PEX).
Atypical haemolytic uraemic syndrome (aHUS) is a renal
thrombotic microangiopathy characterized by excessive com-
plement activation on the surface of the renal microvascula-
ture. It can be both sporadic and familial. Approximately
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and/or acquired abnormality affecting components of the
complement pathway. These include mutations of genes
encoding both complement regulators (factor H, factor I,
CD46 and thrombomodulin) and complement activators (C3
and factor B) (Kavanagh & Goodship, 2011). In the United
Kingdom, criteria for the diagnosis of aHUS have been estab-
lished by the aHUS Rare Disease Group (RDG) (http://rare-
renal.org). The criteria agreed for the diagnosis of aHUS are
shown in Table I. When a patient presents with clinical fea-
tures compatible with a diagnosis of aHUS, all other causes
of a renal thrombotic microangiopathy are excluded with the
investigations listed in Table II. Blood samples to be sent for
measurement ofcomplement levels (C3, C4, factor H and fac-
tor I), mutation screening (CFH, CFI, CD46, C3, CFB, THBD
and DGKE) and detection of factor H autoantibodies should
be undertaken.
Presentation of thrombocytopenia, MAHA and acute anu-
ric/oliguric renal failure requiring dialysis, with no obvious
underlying precipitant, would be in keeping with aHUS and
requires urgent PEX. The caveat to this is late onset congeni-
tal TTP, which has previously been undiagnosed, but may
present with renal failure as a result of recurrent, probably
sub-acute TTP episodes. Therefore, an ADAMTS13 activity
measurement is required, and a sample taken pre-PEX for
exclusion (Fig 1).
The presence of diarrhoea may not always help differenti-
ate these conditions and further investigations to exclude ve-
rotoxin, include stool culture, serology and/or polymerase
chain reaction.
The importance of diagnosis and prompt treatment, spe-
ciﬁcally with PEX in the ﬁrst instance, is to help preserve
renal function in aHUS and in TTP and increase platelet
counts by delivering high volumes of ADAMTS13 present in
plasma, preventing organ sequelae.
Mortality in acute TTP remains at 10–20% and is up to
25% for aHUS, dependent on the mutational trigger. There-
fore, on consideration of these conditions, swift referral and
therapy must be instituted.
The role of ADAMTS13 measurement in TMAs
There remains considerable debate on the role of ADAM-
TS13 measurements in TTP. These are fuelled by the lack of
reproducibility between the various assays using VWF multi-
mers or collagen binding, which provide an indirect measure
of ADAMTS13 (Studt et al, 2003). They could identify very
low ADAMTS13 levels but their reproducibility was poor,
with very high intra-assay coefﬁcients. More recently, ﬂuores-
cence resonance energy transfer (FRETS) assay has become
the main methodology of choice for many institutions
undertaking ADAMTS13 assays, but other assay methods are
used, such as mass spectrometry and enzyme-linked immu-
nosorbent assay, e.g., technozyme (Technoclone, Vienna,
Austria) (Tripodi et al, 2004; Peyvandi et al, 2010).
Atypical HUS, and other TMAs by deﬁnition, will not
have low (<10%) ADAMTS13 activity or the presence of sig-
niﬁcant Anti-ADAMTS13 immunoglobulin G (IgG) autoanti-
bodies. In contrast, idiopathic TTP will have low
ADAMTS13 activity (<10%) and, in the majority of cases
(excluding congenital TTP), antibody can be detected. It has
been suggested that there are cases of normal ADAMTS13
activity in TTP, but in our experience, these have turned out
to be other diagnosis such as aHUS, mainly associated with
CD46 mutations. Assuming a sample has been taken pre-
PEX, a mid range/normal ADAMTS13 is not consistent with
Table I. aHUS diagnostic criteria.
Exclusion
Shiga toxin-associated HUS
Secondary causes
Drugs
Infection (HIV, Streptococcus pneumonia)
Transplantation (bone marrow, liver, lung, cardiac but not de-
novo renal)
Cobalamin deﬁciency
Systemic lupus erythematosus
Antiphospholipid syndrome
Syndrome
Scleroderma
ADAMTS13 antibodies or deﬁciency
Inclusion
Renal biopsy showing a TMA
And/or
The classic triad of microangiopathic haemolytic anaemia,
thrombocytopenia, renal failure
(a)HUS, (atypical) haemaolytic uraemic syndrome; HIV, human
immunodeﬁciency virus; ADAMTS13, a disintegrin and metallopro-
teinase with a thrombospondin type 1 motif, member 13; TMA,
thrombotic microangiopathy.
Table II. Investigations to exclude other causes of a renal throm-
botic microangiopathy.
TTP ADAMTS13 activity
STEC HUS Stool culture
E. coli endotoxin antibodies (IgM)
APL Antibody syndrome APL antibody
SLE DsDNA
HIV HIV test
Scleroderma ANA
Anticentromere antibodies
Anti-ACL-70
Cobalamin C disease Plasma homocysteine levels
Plasma and urine methylmalonic
acid levels
TTP, thrombotic thrombocytopenic purpura; ADAMTS13, a disinte-
grin and metalloproteinase with a thrombospondin type 1 motif,
member 13; STEC-HUS, Shiga-like toxin-producing E. coli haemao-
lytic uraemic syndrome; APL, Antiphospholipid; SLE, Systemic lupus
erythematosus; HIV, human immunodeﬁciency virus; ANA, anti-
nuclear antibodies; ACL, anti-cardiolipin antibody.
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that is not low (<10%) is pancreatitis-associated TTP
(McDonald et al, 2009).
Atypical haemolytic uraemic syndrome may have a normal
ADAMTS13 at presentation or it can be reduced, usually to
about 30–40%. Similar results can be seen in other TMAs,
such as malignant hypertension, scleroderma, autoimmune-
mediated TMA and transplant-associated TMA. The reason
some secondary cases have a normal ADAMTS13 at presen-
tation and some are reduced is unclear. It may be because of
the raised VWF/thrombin levels, which result in consump-
tion of ADAMTS13, but this does not explain the full
picture.
Differentiating TTP from aHUS
It has been suggested that unless there is prompt availability
of ADAMTS13 assays, a serum Creatinine level >150–
200 lmol/l or a platelet count >30 9 10
9/l almost always
eliminates a diagnosis of severe ADAMTS13 deﬁciency
(Zuber et al, 2012a). While the overall Creatinine levels in
TTP cases are not increased and platelet counts are more
usually reduced, i.e., <30 9 10
9/l, in large cohorts, there is
enough evidence in daily practice of patients with TTP who
have renal dysfunction or a platelet count >30 9 10
9/l
(Scully et al, 2008; McDonald et al, 2009; Coppo et al,
2010). However, we would suggest that samples are taken for
ADAMTS13 testing to differentiate the disorders, before
patients initiate PEX.
Treatment
When a diagnosis of an acute TMA has been made, suggest-
ing TTP or aHUS, it is imperative that patients are trans-
ferred to specialist centres for treatment as soon as possible.
How I treat TTP
Thrombotic thrombocytopenic purpura is a haematological
emergency. Referral to an apheresis unit, ensuring central
venous line access and defrosting of plasma, may result in
delays to initiation of treatment. However, patients should
not be left overnight without PEX. Therefore, provision of
centres with a 24/7 apheresis service is required. If there is a
Acute MAHA and 
thrombocytopenia
Acute renal
failure
PEX
Acute TMA-TTP, aHUS  STEC-HUS
 HUS (or congenital TTP) TTP
Neurological/Cardiological
involvement
ADAMTS 13 
testing
*Samples taken 
pre-plasma
therapy
Plus
investigations to
exclude
secondary
causes of TMA 
ADAMTS 13 ≥10%
+/– no evidence of 
Anti-ADAMTS 13 
IgG antibodies: 
aHUS-after secondary
causes excluded
ADAMTS 13 <10%:
Exclude congenital 
TTP
ADAMTS 13 <10%
+ IgG antibodies to 
ADAMTS 13 
aHUS: Eculizumab 
ADAMTS 13 
replacement
Immunosuppressive
therapy, e.g. 
rituximab
Fig 1. Summary in the diagnosis and treat-
ment of TTP and aHUS. TTP, thrombotic
thrombocytopenic purpura; (a)HUS (atypical)
haemaolytic uraemic syndrome; STES-HUS,
Shiga-like toxin-producing E. coli haemaolytic
uraemic syndrome; TMA, thrombotic microan-
giopathy; PEX, plasma exchange; ADAMTS13,
a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13;
IgG, immunoglobulin G.
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infusion should be considered (Scully et al, 2012).
Plasma exchange is the most important treatment, as it
replaces large volume of plasma containing the missing
enzyme and in removes the associated anti-ADAMTS13 IgG
antibody, which is directly related to the pathogenesis of the
disease. In conjunction, high dose steroids, either oral pred-
nisolone or pulsed methylprednisolone, should be used.
While determining the underlying precipitant, steroids
should be considered.
Severe initial disease or progression of symptoms during
admission may require that PEX is intensiﬁed, for example
to twice daily, or increased from 10t o1 5 plasma volumes.
With an improvement in counts and clinical condition, PEX
can be continued as a daily, single plasma volume. There is
no indication to taper PEX, assuming close surveillance once
PEX is stopped.
Further treatment modalities to improve response should
then be instituted. For example, highly active anti-retroviral
therapy (HAART) should be commenced in patients for
whom a diagnosis of HIV-TTP is made. Therapy should be
given after PEX and triple or quadruple therapy is preferable
initially (Hart et al, 2011). As the majority of cases are
idiopathic TTP, with no precipitating cause and antibody-
mediated, further immunosuppressive therapy should be
considered. Ciclosporin is used, with satisfactory results.
However, it is poorly tolerated by patients and currently
rituximab is preferable.
Adjuvant therapy in the treatment of TTP
There is a widespread national and international experience
with rituximab in idiopathic TTP. However, there remain a
number of questions regarding the timing, dose and fre-
quency of therapy and it has not been used in a randomized
control trial setting.
Initial data showed, and conﬁrmed in individual cases, small
series and larger cohorts (relative to the disease incidence), the
beneﬁt of rituximab in relapsing and refractory TTP (Chem-
nitz et al, 2002; Gutterman et al, 2002; Zheng et al, 2003;
Ahmad et al, 2004; Sallah et al, 2004; Fakhouri et al, 2005;
Reddy et al, 2005; Scully et al, 2007; Jasti et al, 2008; Ling
et al, 2009; de la Rubia et al, 2010). Indeed, funding restric-
tions are such that, in some areas, this remains the point at
which rituximab is used. A phase II non-randomized trial to
demonstrate the efﬁcacy and safety of rituximab compared to
historical controls, showed the beneﬁt of Rituximab adminis-
tration in acute TTP. In Caucasian patients, there was a reduc-
tion in the number of PEX required to achieve remission and
an overall (excluding cases treated in the Intensive Care Unit)
reduction in inpatient days, which was also seen in the group
overall compared to historical controls (Scully et al, 2011).
The standard rituximab dose of 375 mg/m
2 has been used
almost extensively in the literature to achieve B cell-depletion
in TTP. There is little evidence of low dose rituximab
regimes in acute disease. Furthermore, despite B cell deple-
tion measured by CD19 levels, they do not always correlate
with ADAMTS13 autoantibody reduction acutely and remis-
sion and are not helpful in predicting relapse.
As per the lymphoma protocol, based on convenience with
other chemotherapy infusions in this disease, rituximab was
used weekly. However, conﬁrmation of clearance of the anti-
CD20 therapy in PEX ﬂuid and a review of peak and trough
rituximab levels with PEX has resulted in a move to infusing
rituximab every 3–4 d (McDonald et al, 2010).
Regardless of the timing of starting Rituximab in an acute
TTP episode, the responses take a median of 10 d. Therefore,
starting Rituximab earlier in an acute episode will result in
reduced PEX, quicker over all responses and reduced inpa-
tient admissions, with signiﬁcant clinical and ﬁnancial bene-
ﬁts (Westwood et al, 2013).
From the phase II trial, an unexpected ﬁnding was the
reduction in relapse rates with acute TTP. Before rituximab,
immunosuppressive therapies had not generally shown a
consistent sustained beneﬁt. This appears, from our historical
control cases, to be as a result of failure to increase the
ADAMTS13 activity by reducing antibody levels. In patients
who do relapse after rituximab, the median time is
24 months, but far longer periods of remission are seen. This
is in contrast to many having had multiple repeated episodes
in the pre-rituximab era and immunosuppressive therapy
that had unacceptable side effects. The low relapse rate was
considerable and conﬁrmed in a further multicentre trial in
relapsed/refractory acute TTP cases presented by the French
collaborative group (Froissart et al, 2012). Previously docu-
mented relapse rates are between 30% and 50%. The Okla-
homa registry had a 34% relapse rate in 60 TTP cases
between 1989 and 2008, with ADAMTS13 activity <10% at
diagnosis (Kremer Hovinga et al, 2010).
Monitoring patients following an episode of acute TTP
In the majority of acute idiopathic TTP cases, treatment is
associated with a reduction in anti-ADAMTS13 IgG levels
and an increase in ADAMTS13 activity. The risk of relapse
of TTP is associated with low ADAMTS activity and or the
presence of antibody. Our practice is to monitor patients in
clinical remission with normal ADAMTS13 activity. A reduc-
tion in enzyme (<10%) is a marker to consider elective treat-
ment with rituximab, which results in normalization of
ADAMTS13 activity and prevents an acute episode (West-
wood et al, 2013).
The reduction in ADAMTS13 activity may occur some
months before relapse, especially in Afro-Caribbean patients,
whereas in Caucasians, relapse typically occurs sooner if left
untreated. ADAMTS13 is a useful surrogate marker of poten-
tial relapse, but the timing of relapse is variable and the use
of prophylactic rituximab may be guided by the patient’s
previous history. Monitoring does not provide an absolute
guarantee against relapse and patients need to be vigilant.
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rituximab (100 mg/m
2), for which an increase in ADAMTS13
activity can be documented and relapse possibly prevented.
Failure to achieve normalization of ADAMTS13 activity
despite remission
There are a small percentage (approximately 5%) of patients
who may attain clinical remission, although this is typically
associated with a longer acute admission, but the ADAM-
TS13 activity does not improve and remains low (<10%).
These patients are very difﬁcult to monitor regarding relapse
and need to seek urgent medical attention for a blood count
if unwell. However, a useful combination has been rituximab
and mycophenolate, which has achieved normalization of
levels in patients who previously have not demonstrated a
rise in ADAMTS13 activity. However, these cases do still
need regular monitoring and if ADAMTS13 activity falls
(<10%), further rituximab therapy is given. Once again,
although not exclusively, these are typically Afro-Caribbean
patients and a further understanding of the pathophysiology
of these cases is required, together with the development of
other therapies.
Other immunosuppressive treatments have been docu-
mented in the literature. Ciclosporin is effective (Cataland
et al, 2007a,b), but we have not used it since the advent of
monoclonal therapy for a number of reasons, including the
risk of relapse during/on stopping treatment. Furthermore,
patients do not tolerate side effects, particularly young
females.
Congenital TTP (also known as Upshaw-Schulman
syndrome)
Despite being a rare subtype, this is increasingly being diag-
nosed, both in young children and late onset associated with
pregnancy. Patients require monitoring of their platelet
counts and therapy to ensure platelets remain >150 9 10
9/l.
The frequency of treatment will vary with the age of presen-
tation and the patient’s genotype. Failure to achieve normal
platelet counts will result in end organ damage, including
renal failure, neurological or cardiac features. Normalization
can be achieved with either plasma infusions (non-UK
sourced and virally inactivated-Octaplas
 ; Octapharma,
Vienna, Austria) or with an intermediated purity Factor VIII
concentrate, which contains measurable ADAMTS13 (Bio-
Products Laboratory, Elstree, Herts, UK).
In women of child-bearing age, pregnancy requires regular
plasma infusion throughout to ensure improved outcomes
for mother and baby.
Pregnancy-associated TTP
Pregnancy may be a precipitant of TTP in a small proportion
of cases and ADAMTS13 analysis is required to differentiate
congenital from acquired TTP. TMAs in pregnancy can be
difﬁcult to differentiate, e.g., pre-eclampsia (PET), HELLP
syndrome (haemolysis, elevated liver enzyme levels, and low
platelet counts) and TTP. In general, HUS occurs in the
postpartum period. TTP may be associated with features sug-
gestive of PET or HELLP. As a general guide, PEX should be
started in patients with platelet counts <50 9 10
9/l and
MAHA features or the presence of clinical features possibly
suggestive of TTP at higher platelet counts.
How do I treat incident patients with aHUS?
Until recently it was recommended that all patients present-
ing with aHUS should be offered a trial of PEX and/or
plasma infusions (Taylor et al, 2010). Despite this, the
majority of patients need long term renal replacement ther-
apy within 2 years of presentation (Noris et al, 2010). With
the ﬁnding that excessive activation of the alternative path-
way of complement underlies the pathogenesis of aHUS in
most patients, it became clear that complement inhibition
would be a logical therapy. Eculizumab is the only comple-
ment inhibitor currently licensed for any indication. It was
ﬁrst introduced for the treatment of paroxysmal nocturnal
haemoglobinuria (Hillmen et al, 2006) and long term data
has shown its efﬁcacy in this disease (Kelly et al, 2011).
Anecdotal reports of its efﬁcacy in aHUS (Gruppo & Rother,
2009; Nurnberger et al, 2009) led to clinical trials, the results
of which have recently been published (Legendre et al, 2013).
These showed that eculizumab was a highly effective treat-
ment for aHUS in patients who were either resistant to PEX
or dependent on regular PEX to maintain remission. Based
on these results, in 2011 both the US Food and Drug
Administration (FDA) and the European Medicines Agency
(EMA) approved the use of eculizumab for the treatment of
aHUS. In England an application was submitted to the Advi-
sory Group for National Specialised Services (AGNSS) for a
national service for aHUS, including funding for eculizumab.
This was considered by AGNSS in June 2012. In January
2013 it was announced that. ‘they concluded that eculizumab
would help save lives and improve the quality of life for chil-
dren (among whom the condition is particularly prevalent)
and adults with atypical haemolytic uraemic syndrome.’
(http://www.specialisedservices.nhs.uk/document/ecu-
lizumab-treatment-atypical-haemolytic-uraemic-syndrome/).
Subsequently ‘Ministers agreed with AGNSS that there is evi-
dence for the clinical effectiveness of eculizumab for the
treatment of atypical haemolytic uraemic syndrome but
wanted further advice on the affordability of the drug’. Min-
isters have asked NICE to consider eculizumab for the treat-
ment of atypical haemolytic uraemic syndrome as part of its
new Highly Specialised Technologies programme.’ The out-
come of the National Institute for Health and Care Excel-
lence (NICE) evaluation will be announced in 2014. In the
meantime, National Health Service (NHS) England has pub-
lished a Clinical Commissioning Policy Statement on the use
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tent/uploads/2013/09/e03-hss-a.pdf). This states that NHS
England will commission eculizumab for new patients with
aHUS and for patients who are on dialysis and are suitable
for a kidney transplant. In England, we are therefore now
able to treat all new patients with aHUS. This service is
delivered locally but coordinated through the expert centre
in Newcastle. When a patient presents with features compati-
ble with a diagnosis of aHUS we request that the investiga-
tions listed in Table II are undertaken. We try to initiate
treatment with eculizumab as soon as possible because the
clinical trials have suggested that the sooner that treatment is
started, the greater is the chance of recovery of renal
function. The only result that we request be available is the
ADAMTS13 activity. If the ADAMTS13 activity is not
immediately available we recommend that treatment with
PEX is commenced and continued until the result is avail-
able. Provided that the ADAMTS13 activity is not <10% and
that the clinical features are compatible with a diagnosis of
aHUS we, with the approval of NHS England, authorize the
onset of treatment with eculizumab. If subsequent investiga-
tions show that the thrombotic microangiopathy is due to
another condition apart from aHUS, then eculizumab is
withdrawn. The results of the genetic investigations are avail-
able within 8 weeks.
Two groups have recently published reports of mutations
in the DGKE gene, encoding diacylglycerol kinase epsilon
(DKGE) in young children with the clinical phenotype of
aHUS (Lemaire et al, 2013; Ozaltin et al, 2013). DGKE is a
lipid kinase that catalyses the conversion of diacylglycerol to
phosphatidic acid. Failure of this leads to increased protein
kinase C activity and it has been postulated that this is
responsible for the development of a TMA (Quaggin, 2013).
This form of aHUS presents usually in the ﬁrst year of life
and does not respond to eculizumab. The mutations in
DGKE are either homozygous or compound heterozygous. If,
on screening, we ﬁnd such changes in DGKE in the absence
of any mutations in complement genes, then we will consider
withdrawing eculizumab.
The markers of an active TMA (thrombocytopenia, micro-
angiopathic haemolytic anaemia, elevated lactate dehydroge-
nase, low haptoglobin) respond rapidly to treatment with
eculizumab in virtually all patients with an underlying com-
plement abnormality. In aHUS, whether renal function
returns is dependent on the extent of irreversible renal dam-
age sustained before the onset of treatment. In both anec-
dotal reports and the trials it has been found that some
patients who are on dialysis at the onset of the treatment will
recover sufﬁcient renal function to stop dialysis. This can
take several months. We, therefore, currently would not con-
sider withdrawing eculizumab in a dialysis-dependent patient
until they had received at least 4 months treatment with ecu-
lizumab. If eculizumab is withdrawn in such a patient then
we monitor closely the TMA markers. If there is any
evidence of recurrent extra-renal TMA then eculizumab is
reinstituted. The other group of patients in whom we will
consider withdrawing eculizumab is those in whom we sub-
sequently ﬁnd a mutation in CD46 in the absence of changes
in any other gene. We counsel this patient that there is a risk
of recurrent disease and withdrawal of the eculizumab is only
undertaken if the patient agrees to this. If not then they con-
tinue on eculizumab indeﬁnitely.
At present, in all other patientswe continue treatment with
eculizumab indeﬁnitely. The major risk associated with ecu-
lizumab treatment is the development of meningococcal dis-
ease. All patients are vaccinated with a tetravalent vaccine
before the onset of treatment and, in addition, receive long-
term prophylactic antibiotics (either penicillin or erythromy-
cin) because current vaccines do not cover Serogroup B
strains. We will in the future be testing the response to vacci-
nation after 12 weeks and re-vaccinating if the response is
suboptimal.
How do I treat prevalent aHUS patients?
The outcome of renal transplantation alone in aHUS patients
on dialysis has been well documented to be poor, with a high
rate of graft loss due to recurrent disease (Bresin et al, 2006;
Le et al, 2013). Because of this, many patients known to have
complement abnormalities associated with a high risk of
recurrence have not been listed for a transplant. In those
patients known to have mutations in the genes encoding
complement proteins synthesized predominantly by the liver
(such as factor H and factor I), combined liver-kidney trans-
plant is an alternative therapeutic strategy that can be suc-
cessful (Saland et al, 2009). However, the 1-year patient
survival for this procedure is not as high as would be
expected with a kidney transplant alone. Because of this and
the advent of eculizumab, many patients do not opt for this
procedure. Both anecdotal reports and trial data have shown
that eculizumab can be used successfully to both treat and
prevent recurrent disease post-transplant (Zuber et al,
2012b). In England, aHUS patients on dialysis are now,
therefore, being listed for a kidney transplant that is covered
by eculizumab given immediately prior to transplantation
and then long term to prevent recurrent disease. Whether in
any of these patients it will be safe to withdraw eculizumab
at a later stage not yet known.
There are a small number of aHUS patients who respond
to PEX, but need long-term therapy to maintain their remis-
sion. Most of these patients entered the clinical trials and are
now receiving long-term eculizumab. We recommend that
those few who are still on PEX should be started on ecu-
lizumab and PEX withdrawn.
There are also a small number of patients who have
responded to PEX and have stayed in remission without any
prophylactic therapy. Screening in some of these patients has
shown a pathogenic complement gene mutation. We believe
that such patients are potentially at risk of recurrent disease
in the future. Whether this warrants prophylactic treatment
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Conclusion
The initial diagnosis and treatment of TMAs, speciﬁcally
TTP and aHUS with PEX remains paramount, but is more
justiﬁed as we understand different disease states. However,
determining the underlying pathophysiology and diagnosis is
relevant when further therapeutic modalities need to be
introduced into the treatment pathway. The advent of
eculizumab has dramatically changed the prognosis of aHUS.
It is now possible that early treatment will prevent irreversible
renal failure in patients who present for the ﬁrst time and
that recurrent disease can be prevented in those patients
undergoing renal transplantation. Similarly, prompt diagnosis
and initiation of PEX and monoclonal anti-CD20 treatment
in TTP has improved response and relapse rates.
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